To complement these transcript-level observations, protein abundance data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (Li et al., 2023) were analyzed via the UALCAN platform (Chandrashekar et al., 2022) to assess RPB1 expression (Figure 1B). Here, POLR2A is linked to neoplasm.